Recent advances in the field of tubulin polymerization inhibitors

References

• Jordan MA, Hadfield JA, Lawrence NJ, McGown AT Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res. Rev 18, 259–296 (1998).
   PubMed Web of Science ®Google Scholar
• Li Q, Sham HL, Rosenberg SH. Antimitotic agents. Ann. Rep. Med. Chem. 34, 139–148 (1999).
   Google Scholar
• von Angerer E. New inhibitors of tubulin polymerisation. Exp. Opin. Ther. Patents 9, 1069–1081 (1999).
   Web of Science ®Google Scholar
• •Thorough and comprehensive review, covers the patent literature of tubulin polymerization inhibitors for 1996-1999.
   Google Scholar
• Jimenez-Barbero J, Amat-Guerri F, Snyder JP. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. CUIT: Med. Chem. AntiCancer Agents2, 91–122 (2002).
   Google Scholar
• Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol The]: 52, 35–84 (1992).
   Google Scholar
• Dumontet C, Sikic BI. Mechanism of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Gun. awl. 3, 1061–1070 (1999).
   Google Scholar
• Fardel 0, Lecureur V, Guillouzo A. The P- glycoprotein multidrug transporter. Gen. Pharmacol 27, 1283–1291 (1996).
   Google Scholar
• Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20, 931–940 (1998).
   PubMed Web of Science ®Google Scholar
• Hussain M, Wozniak AJ, Edelstein MB. Neurotoxicity of antineoplastic agents. Grit. Rev Oncol Hematol 14, 61–75 (1993).
   PubMed Web of Science ®Google Scholar
• Windebank AJ. Chemotherapeutic neuropathy. Curr. Opin. Neurol 12, 565–571 (1999).
   PubMed Web of Science ®Google Scholar
• Hastie SB. Interactions of colchicine with tubulin. Pharmacol The]: 51, 377–401 (1991).
   PubMed Web of Science ®Google Scholar
• Nogales E, Wolf SG, Downing KH. Structure of the a/I3 tubulin dimer by electron crystallography. Nature. 391, 199–203 (1998).
   Google Scholar
• Uckun FM, Mao C, Vassilev AO, Huang H, Jan ST Structure-based design of a novel synthetic spiroketal pyran as a pharmacophore for the marine natural product spongistatin 1. Bioorg. Med. Chem. Lett. 10, 541–545 (2000).
   Google Scholar
• Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of taxol in I3-tubulin: a model based on electron crystallographic density. Proc. Natl Acad. Li. USA 98, 5312–5316 (2001).
   Google Scholar
• Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45, 209–211 (1989).
   Google Scholar
• Pettit GR, Singh SB, Boyd MR et al Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. J. Med. Chem. 38, 1666–1672 (1995).
   Google Scholar
• Pettit GR, Rhodes MR. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des. 13, 183–191 (1998).
   Google Scholar
• Tozer GM, Prise VE, Wilson J et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59, 1626–1634 (1999).
   PubMed Web of Science ®Google Scholar
• Gwaltney SL, Imade HM, Barr KJ et al. Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg. Med Chem. Lett. 11, 871–874 (2001).
   Google Scholar
• DUCki S, Forrest R, Hadfield JA etal. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. 8, 1051–1056 (1998).
   PubMed Web of Science ®Google Scholar
• Lawrence NJ, McGown AT, Ducki S, Hadfield JA. The interaction of chalcones with tubulin. Anti-Cancer Drug Des. 15, 135–141 (2000).
   PubMedGoogle Scholar
• Ohsumi K, Hatanaka T, Fujita K et al. Synthesis and antitumor activity of cis-restricted combretastatins: five membered heterocyclic analogues. Bioorg. Med. Chem. Lett. 8, 3153–3158 (1998).
   PubMed Web of Science ®Google Scholar
• Wu-Wong JR, Alder JD, Alder L et al. Identification and characterization of A-105972, an antineoplastic agent. Cancer Res. 61(4), 1486–1492 (2001).
   Google Scholar
• Tahir SK, Han EKH, Credo B et al A-204197, a new tubulin binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 61(14), 5480–5485 (2001).
   Google Scholar
• Li Q, Woods KW, Claiborne A et al. Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg. Med. Chem. Lett. 12, 465–469 (2002).
   Google Scholar
• Wang L, Woods KW, Li Q et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumour activity evaluation. J. Med. Chem. 45, 1697–1711 (2002).
   Google Scholar
• ••Interesting report including an orally-active imidazole-based combretastatin derivative.
   Google Scholar
• Pinney KG, Bounds AD, Dingeman KM et al. A new anti-tubulin agent containing the benzo [b]thiophene ring system. Bioorg. Med. Chem. Lett. 9, 1081–1086 (1999).
   PubMedGoogle Scholar
• Flynn BL, Flynn GP, Hamel E, Jung MK. The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. 11, 2341–2343 (2001).
   Google Scholar
• Bacher G, Nickel B, Emig P etal. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficiacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res. 61, 392–399 (2001).
   Google Scholar
• ••Report on a novel orally-active tubulinpolymerization inhibitor, being efficient against MDR (+) tumors and lacking neurotoxicity.
   Google Scholar
• Gastpar R, Goldbrunner M, Marko D, von Angerer E. Methoxy-substituted 3-formy1-2-phenylindoles inhibit tubulin polymerization. J. Med. Chem. 41, 4965–4972 (1998).
   Google Scholar
• Medarde M, Ramos AC, Caballero E etal. Synthesis and anti-neoplastic activity of combretastatin analogues: heterocombretastatins. FIR: J. Med. Chem. 33, 71–77 (1998).
   Google Scholar
• Medarde M, Ramos AC, Caballero E etal. Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg. Med. Chem. Lett. 9, 2303–2308 (1999).
   Google Scholar
• Mahboobi S, Pongratz H, Hufsky H et al. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J. Med. Chem. 44, 4535–4553 (2001).
   Google Scholar
• Gourley M, Williamson JS. Angiogenesis: New targets for the development of anticancer chemotherapies. Curr Pharm. Des 6, 417–439 (2000).
   PubMed Web of Science ®Google Scholar
• Leoni LM, Hamel E, Genini D et al Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J. Nati Cancer Inst. 92, 217–222 (2000).
   PubMed Web of Science ®Google Scholar
• •Report on a novel tubulin polymerization inhibitor that inhibits the growth of nondividing cells and shows toxicity towards MDR-positive cells.
   Google Scholar
• Shih H, Deng L, Carrera CJ, Adachi S, Cottam HB, Carson DA. Rational design, synthesis and structure-activity relationships of antitumor CO -2-benzylidene-l-tetralones and (4-2-benzylidene-1-indanones. Bioorg. Med. Chem. Lett. 10, 487–490 (2000).
   Google Scholar
• Uckun FM, Mao C, Jan ST etal. SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity. C1117: Opin. Investig Drugs. 1,252-256 (2000). Provides instructive examples for the rational design of tubulin polymerization inhibitors.
   Google Scholar
• Uckun FM, Mao C, Jan ST et a/. Spongistatins as tubulin targeting agents. C1117: Pharm. Des. 7, 1291–1296 (2001).
   Google Scholar
• Pettit GR, Cichacz ZA, Gao F et al Isolation and structure of spongistatin 1. J. Org. Chem. 58, 1302–1304 (1993).
   Google Scholar
• Uckun FM, Mao C, Vassilev AO, Navara CS, Narla RKS, Jan ST A rationally designed anticancer drug targeting a unique binding cavity of tubulin. Bioorg. Med. Chem. Lett. 10, 1015–1018 (2000).
   PubMedGoogle Scholar
• Poncet J. The dolastatins, a family of promising antineoplastic agents. C1117: Pharm. Design 5, 139–162 (1999).
   Google Scholar
• Bai R, Taylor GF, Schmidt JM et al Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions. Md. Pharmacol 47, 965–976 (1995).
   Google Scholar
• Fotsis T, Zhang, Y, Pepper MS et al The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368, 237–239 (1994).
   PubMed Web of Science ®Google Scholar
• Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin. Cancer Res. 5, 493–499 (1999).
   Google Scholar
• Cushman M, He HM, Katzenellenbogen JA et at Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J. Med Chem. 40, 2323–2334 (1997).
   Google Scholar
• Wang Z, Yang D, Mohanakrishnan AK et al Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability. J. Med. Chem 43, 2419–2429 (2000).
   PubMedGoogle Scholar
• ••Interesting report on synthesis andbiological effects of B-ring expanded steroid derivatives with compounds showing paclitaxel-like properties, while others are similar to colchicine.
   Google Scholar
• Verclier-Pinard P, Wang Z, Mohanakrishnan AK, Cushman M, Hamel E. A steroid derivative with paclitaxel-like effects on tubulin polymerization. Md. Pharmacol 57, 568–575 (2000).
   Google Scholar
• Gerwick WH, Proteau PJ, Nagle DG, Hamel E, Blokhin A, Slate D. Structure of curacin A, a novel antimitotic, antiproliferative, and brine shrimp toxic natural product from the marine cyanobacterium Lyngbia majuscula. J. Org. Chem 59, 1243–1245 (1994).
   Web of Science ®Google Scholar
• Blokhin AV, Yoo HD, Geralds RS, Nagle DG, Gerwick WH, Hamel E. Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogues. Mol Pharmacol 48, 523–531 (1995).
   PubMedGoogle Scholar
• Verclier-Pinard P, Sitachitta M, Rossi JV, Sackett DL, Gerwick WH, Hamel E. Biosynthesis and radiolabeled curacin A and its rapid and apparently irreversible binding to the colchicine site of tubulin. Arch. Biochem. Biophys. 370, 51–58 (1999).
   Google Scholar
• Kanoh K, Kohno S, Katada J, Takahashi J, Uno I. 0 -Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization. J. Antibiot. (76 lryo) 52, 134–141 (1999).
   Google Scholar
• Kanoh K, Kohno S, Katada J, Takahashi J, Uno I, Hayashi Y. Synthesis and biological activities of phenylahistin derivatives. Bioorg. Med. Chem. 7, 1451–1457 (1999).
   PubMed Web of Science ®Google Scholar
• Legault J, Gaulin JF, Mounetou E et al. Microtubule disruption induced in vivo by alkylation of 13-tubulin by 1 aryl 3 (2 chloroethyl)ureas, a novel class of soft alkylting agents. Cancer Res. 60, 985–992 (2000).
   PubMedGoogle Scholar
• Medina JC, Shan B, Beckmann H et al Novel antineoplastic agents with efficacy against multidrug resistant tumor cells. Bioorg. Med. Chem. Lett. 8, 2653–2656 (1998).
   PubMed Web of Science ®Google Scholar
• Shan B, Medina JC, Santha E et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Nati Acad. Sci. USA 96, 5686–5691 (1999).
   Google Scholar
• Combeau C, Provost J, Lancelin F et al RPR112378 and RPR115781: two representatives of a new family of microtubule assembly inhibitors. Md. Pharmacol 57, 553–563 (2000).
   Google Scholar
• Hill BT Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. C1117: Pharm. Des. 7, 1199–1212 (2001).
   Google Scholar
• Fumoleau P, Raymond E, Bennouna J et al Phase I trial of vinflunine (L0070) a novel fluorinated vinca alkaloid in patients (pts) with advanced solid malignancies: final results. Proc. Am. Assoc. Cancer Res. 42, 834 (2001).
   Google Scholar
• Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel action of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 60, 5045–5051 (2000).
   PubMed Web of Science ®Google Scholar
• Etievant C, Kruczynski A, Barret JM, Tait AS, Kavallaris M, Hill BT Markedly diminished drug resistance-inducing properties of vinflunine (20 ',20 '-difluoro-3 ',4"-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother. Pharmacol 48, 62–70 (2001).
   Google Scholar
• Hill BT, Fiebig HH, Waud WR, Poupo MF, Colpaert F, Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Etll: Cancer35, 512–520 (1999).
   Google Scholar
• Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br. Cancer 84, 290–295 (2001).
   Google Scholar